UBS Maintains Buy on AnaptysBio, Raises Price Target to $76
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
UBS analyst Michael Yee maintains AnaptysBio (NASDAQ:ANAB) with a Buy and raises the price target from $60 to $76.
UBS analyst Michael Yee maintains AnaptysBio (NASDAQ:ANAB) with a Buy and raises the price target from $60 to $76.